Related Experiment Video
Updated: May 10, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Targeted Glioma Therapy via TMVP1 Peptide-Modified FLT4 Liposomes: A Novel Molecular Probe Strategy
Yuzhu Zhou1,2, Liwen Chen1,2, Chao Shang1
1Department of Neurobiology, School of Life Sciences, China Medical University, Shenyang, Liaoning, 110022, People's Republic of China.
Introduction:
Glioma is the most common primary malignant tumor in the brain, characterized by rapid growth, strong invasiveness, and unclear lesion boundaries. Current drug treatments have the problems of weak targeting and poor therapeutic effect. TMVP1 is a tumor-targeting peptide that specifically binds to FLT4, a receptor involved in glioma angiogenesis. Its high affinity and selectivity for FLT4 make it an ideal candidate for targeted drug delivery. By functionalizing TMZ-loaded liposomes with TMVP1 (TMZ@Lip-TMVP1), we aimed to enhance glioma-specific targeting and therapeutic efficacy.
Methods:
FLT4 was validated as a therapeutic target for glioma by bioinformatics analysis, RT-qPCR, and immunofluorescence experiments. The targeting ability of TMVP1 to FLT4 was confirmed using colocalization and surface plasmon resonance (SPR) experiments. The physicochemical properties of TMZ@Lip-TMVP1, including potential, particle size, TMZ encapsulation efficiency, and peptide coupling rate, were characterized. In vitro cytotoxicity tests were performed to evaluate biocompatibility and therapeutic efficacy. In addition, the targeted delivery and therapeutic impact of TMZ@Lip-TMVP1 were evaluated in subcutaneous tumor-bearing nude mice.
Results:
Based on bioinformatics, RT-qPCR, and immunofluorescence results, FLT4 was identified as a reliable therapeutic target for glioma. Colocalization and SPR experiments showed that TMVP1 could effectively bind to FLT4. TMZ@Lip-TMVP1 had good stability and physicochemical properties. Cytotoxicity experiments showed that liposome microcapsules had good biocompatibility, and TMZ@Lip-TMVP1 significantly enhanced the killing effect on glioma cells compared with unmodified liposomes. In vivo experiments showed that TMZ@Lip-TMVP1 could effectively target FLT4 and improve the therapeutic effect of glioma mouse models.
Discussion:
The results confirmed that TMZ@Lip-TMVP1 can efficiently deliver TMZ to glioma cells by targeting FLT4, improving the therapeutic effect. This targeted delivery platform provides a promising approach for glioma treatment. In addition, the modular nature of this molecular probe system allows functional adjustment by modifying the coating material, which may enable wider applications in targeted drug delivery and precision medicine.
Insights
This study developed TMVP1-functionalized liposomes (TMZ@Lip-TMVP1) for targeted glioma treatment. These liposomes effectively deliver chemotherapy drugs to glioma cells by targeting FLT4, significantly improving therapeutic outcomes in mouse models.
Area of Science:
- Biomedical Engineering
- Oncology
- Drug Delivery Systems
Background:
- Glioma, a common brain tumor, presents challenges in treatment due to poor drug targeting and efficacy.
- Existing therapies struggle with specificity, leading to off-target effects and limited therapeutic impact.
- FLT4 has been identified as a key receptor involved in glioma angiogenesis, presenting a potential therapeutic target.
Purpose of the Study:
- To develop a targeted drug delivery system for glioma using TMVP1 peptide functionalized liposomes carrying temozolomide (TMZ@Lip-TMVP1).
- To enhance the specific targeting of glioma cells and improve the therapeutic efficacy of chemotherapy.
- To evaluate the in vitro and in vivo performance of the developed targeted delivery platform.
Main Methods:
- FLT4 validation as a glioma target using bioinformatics, RT-qPCR, and immunofluorescence.
- Confirmation of TMVP1 binding to FLT4 via colocalization and surface plasmon resonance (SPR).
- Characterization of TMZ@Lip-TMVP1 physicochemical properties, in vitro cytotoxicity, and in vivo efficacy in tumor-bearing mice.
Main Results:
- FLT4 was confirmed as a viable therapeutic target for glioma.
- TMVP1 demonstrated effective binding to FLT4, validating its targeting capability.
- TMZ@Lip-TMVP1 exhibited favorable physicochemical properties, good biocompatibility, and significantly enhanced glioma cell killing in vitro and in vivo.
- Targeted delivery of TMZ via TMVP1-functionalized liposomes improved therapeutic effects in glioma models.
Conclusions:
- TMZ@Lip-TMVP1 provides an effective platform for targeted delivery of chemotherapy to glioma by leveraging FLT4 specificity.
- This approach significantly enhances therapeutic efficacy compared to non-targeted liposomes.
- The modular design offers potential for broader applications in precision medicine and targeted drug delivery for various cancers.
More Related Videos
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
